|
Eye aging, what can be done?
by Robert Mason Ph.D.
Over the past few years numerous attempts have been
made to prevent and reverse age related disorders of vision, particularly those associated
with cataracts, using conventional methods of treatment.
No pharmaceutical preparation could be clinically
proven to provide an absolutely reliable therapy. More recently however, research work in
the field of molecular biology and careful, detailed studies, carried out over a total of
12 years, has yielded very encouraging results.
Age related disorders of vision and cataract can
indeed be influenced, if they are treated with special organ lysates, derived from various
tissues of the eye, as contained in the German company VitOrgan product called Conjunctisan
A.
Cataract is mainly due to disturbed energy exchange,
impaired proteins and cross-linking of protein molecules. As the protoplasmic cellular
factors of Conjunctisan A improve the supply of energy, they have a favorable influence on
lenticular transparency.
Numerous clinical reports have presented convincing
evidence to confirm the efficiency of Conjunctisan A, a success rate in improvement of
vision for 65% of Cataract sufferers.
Previously it was thought that senile Cataract and
associated disorders of vision could only be treated by surgery. This has now been
superseded in the findings of the long-term study, on 356 eyes treated with Conjunctisan
A.
The ability of Conjunctisan A to improve the
condition of vision has benefits on its ability to prevent deterioration and prolong the
normal vision in older individuals.
As Conjunctisan A has now been available in Europe
for over 12 years, it has been tolerated extremely well, even in prolonged usage there are
no known side effects.
to order
ALL INFORMATION IS EDUCATIONAL
AND SHOULD NOT REPLACE THE ADVICE OF YOUR PHYSICIAN.
The above article is copyrighted and may not be
copied without the written permission of International Antiaging Systems, Les
Autelets Suite A, Sark GY9 0SF, Channel Islands, Great Britain.
| 
